Eloxx Pharmaceuticals in the spotlight (part V)

Analyzing latest data and upcoming combination data play

Eloxx (ELOX) shared monotherapy data from their Phase 2 in cystic fibrosis last month (see our previous posts covering ELOX). The data that was reported was not bad, but it left investors wanting more. More data was expected, and it wasn’t shared. Generally, lack of transparency leads investors to believe that the company was not comfortable sharing dat…